Coya Therapeutics’ (COYA) Buy Rating Reaffirmed at D. Boral Capital

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating restated by stock analysts at D. Boral Capital in a report issued on Monday,Benzinga reports. They presently have a $15.00 price target on the stock. D. Boral Capital’s target price would suggest a potential upside of 234.08% from the stock’s current price.

COYA has been the topic of a number of other research reports. Chardan Capital reiterated a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a research report on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Wednesday, January 21st. Finally, HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Coya Therapeutics in a research note on Monday, February 2nd. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Coya Therapeutics has an average rating of “Moderate Buy” and an average price target of $16.00.

Coya Therapeutics Trading Down 0.9%

COYA traded down $0.04 during trading on Monday, hitting $4.49. 140,310 shares of the company traded hands, compared to its average volume of 208,863. The company has a market cap of $93.93 million, a PE ratio of -4.04 and a beta of 0.23. The stock’s 50-day simple moving average is $4.77 and its two-hundred day simple moving average is $5.59. Coya Therapeutics has a 1 year low of $3.94 and a 1 year high of $7.75.

Coya Therapeutics (NASDAQ:COYA) last released its quarterly earnings results on Tuesday, March 17th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.26). The firm had revenue of $3.96 million for the quarter, compared to analysts’ expectations of $1.93 million. Coya Therapeutics had a negative net margin of 462.24% and a negative return on equity of 55.76%. Equities analysts expect that Coya Therapeutics will post -1.15 EPS for the current year.

Institutional Trading of Coya Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. acquired a new position in Coya Therapeutics during the 3rd quarter valued at approximately $28,000. CIBC Private Wealth Group LLC acquired a new stake in shares of Coya Therapeutics during the fourth quarter worth $47,000. Occudo Quantitative Strategies LP purchased a new stake in shares of Coya Therapeutics during the fourth quarter valued at $66,000. Lantern Wealth Advisors LLC purchased a new stake in shares of Coya Therapeutics during the third quarter valued at $66,000. Finally, Oppenheimer & Co. Inc. acquired a new position in shares of Coya Therapeutics in the 4th quarter valued at $81,000. 39.75% of the stock is currently owned by institutional investors and hedge funds.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.